Press Releases
Click here to be added to our mailing list2013
-
May 15, 2013
Nicox: first quarter 2013 financial results -
April 26, 2013
Vicente Anido, Jr. nominated for election to Nicox’s Board of Directors -
April 23, 2013
Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference -
March 22, 2013
Nicox 2012 Financial Results and Business Update -
March 18, 2013
Nicox strengthens its European and International Operations team and expands its product pipeline -
January 29, 2013
Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from Nicox
Archive
See more 2012-
November 09, 2012
Nicox attends 2012 AAO Meeting in Chicago -
October 25, 2012
Nicox reports financial results for the nine months to September 2012 -
October 22, 2012
Nicox launches AdenoPlus™ in the United States -
August 28, 2012
Nicox strengthens US commercial team -
July 27, 2012
Nicox first half 2012 financial results -
June 21, 2012
Nicox signs worldwide licensing agreement with Rapid Pathogen Screening, Inc. for ophthalmic diagnostics -
June 01, 2012
Nicox Board decides not to exercise its option to acquire the remaining shares of Altacor -
May 10, 2012
Nicox reports first quarter 2012 financial results -
April 04, 2012
Nicox provides update on U.S. regulatory status of naproxcinod -
April 02, 2012
Nicox appoints Philippe Masquida EVP, Managing Director of European Operations -
March 21, 2012
Nicox enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business -
March 21, 2012
Jerry St. Peter appointed Executive Vice President and General Manager of Nicox Inc. -
March 13, 2012
Nicox, Bausch + Lomb Glaucoma Candidate BOL-303259-X Meets Primary Endpoint in Phase 2b Study; Bausch + Lomb to Pursue Global Phase 3 Development Program -
February 29, 2012
Nicox 2011 Financial Results
See more 2011
-
December 01, 2011
Update on Nicox's business activities -
November 28, 2011
Nicox: Patient recruitment completed by Bausch + Lomb in glaucoma study -
October 27, 2011
Nicox reports financial results for the nine months to September 2011 -
September 19, 2011
Nicox presents new preclinical data for NCX 6560 -
July 29, 2011
Nicox first half 2011 financial results -
May 30, 2011
Nicox presents first preclinical data in Pulmonary Arterial Hypertension research program -
May 04, 2011
Nicox reports first quarter 2011 financial results -
April 20, 2011
Nicox withdraws its Marketing Authorization Application for naproxcinod in Europe -
March 18, 2011
Nicox and Ferrer enter into option agreement for naproxcinod -
February 24, 2011
Nicox 2010 Financial Results
See more 2010
-
November 18, 2010
Nicox presents NCX 6560 phase 1b results at AHA -
November 15, 2010
Nicox's partner Bausch + Lomb initiates phase 2b study with glaucoma drug-candidate BOL-303259-X (NCX 116) -
November 03, 2010
Nicox announces financial results for the first three quarters of 2010 and provides update on business restructuring -
September 15, 2010
Nicox and Merck to broaden scope of license agreement -
August 04, 2010
Nicox to close US headquarters -
July 30, 2010
Nicox first half 2010 financial results -
July 22, 2010
FDA provides Complete Response Letter to Nicox's New Drug Application for naproxcinod -
June 28, 2010
Presentation of preclinical data for Nicox's ophthalmology candidate NCX 434 -
June 22, 2010
Nicox: Presentation at ESH congress -
June 21, 2010
Nicox: Presentations at EULAR congress -
June 01, 2010
Nicox: Presentation of promising preclinical results in the fields of ophthalmology and pain -
May 19, 2010
Nicox provides strategic update -
May 13, 2010
Nicox provides update on FDA Advisory Committee Meeting for naproxcinod -
May 11, 2010
Posting of Briefing Documents for FDA Advisory Committee on NicOx's naproxcinod - Company to host conference calls on Thursday May 13 -
May 07, 2010
Nicox reports first quarter 2010 financial results -
May 03, 2010
Pooled phase 3 blood pressure results for Nicox's naproxcinod presented at the American Society of Hypertension (ASH) -
March 22, 2010
Nicox: Publication of naproxcinod phase 3 data in Osteoarthritis and Cartilage -
March 08, 2010
Nicox announces FDA Advisory Committee to discuss naproxcinod on May 12 -
March 04, 2010
Nicox 2009 Financial Results -
March 03, 2010
Nicox and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116 -
January 22, 2010
Nicox announces EMEA validation of naproxcinod MAA submission -
January 12, 2010
Nicox and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
See more 2009
-
December 22, 2009
Nicox submits naproxcinod MAA to the EMEA -
November 18, 2009
Nicox announces FDA accepts naproxcinod NDA for filing -
November 18, 2009
Nicox announces FDA accepts naproxcinod NDA for filing -
November 13, 2009
Nicox announces NCX 6560 meets primary and secondary objectives in first-in-man study -
October 22, 2009
Report of Nicox's financial results for the first three quarters of 2009 -
October 20, 2009
Nicox presents 26 week naproxcinod efficacy data at American College of Rheumatology -
September 25, 2009
Nicox submits New Drug Application (NDA) for naproxcinod to the US FDA -
September 22, 2009
Important data for Nicox naproxcinod published in the American Journal of Cardiology -
September 14, 2009
Nicox makes three scientific presentations at the 2009 World Congress on Osteoarthritis -
August 06, 2009
Nicox reacquires rights to PF-03187207 for glaucoma from Pfizer -
July 29, 2009
Nicox first half 2009 financial results: naproxcinod nearing regulatory submissions in US and Europe -
June 15, 2009
Nicox: additional 24 hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension -
June 12, 2009
Nicox presents naproxcinod results in several posters at EULAR -
June 09, 2009
Nicox publishes results of the ZEST phase 2 study for naproxcinod -
May 19, 2009
Nicox presents phase 3 quality of life data for naproxcinod at ISPOR -
May 13, 2009
Nicox reports first quarter 2009 financial results -
May 07, 2009
Analyses of phase 3 blood pressure data for Nicox naproxcinod presented at ASH -
May 05, 2009
Nicox co-presents four posters on PF 03187207 for glaucoma at ARVO with Pfizer Inc -
April 23, 2009
Nicox acquires Nitromed s NO-donating patents -
March 31, 2009
New analyses of phase 3 data for Nicox naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting -
March 18, 2009
Nicox initiates proof-of-principle clinical study for NCX 6560 -
February 26, 2009
Financial results for full year 2008: Nicox in a unique position to deliver significant shareholder value
See more 2008
-
December 23, 2008
Nicox announces results for TPI 1020 in COPD -
December 19, 2008
Nicox naproxcinod shows differentiated 24-hour blood pressure profile after 13 weeks treatment -
December 17, 2008
Nicox naproxcinod shows robust blood pressure results in phase 3 pooled analysis -
December 02, 2008
Nicox signs agreement with DSM for the commercial manufacture of naproxcinod drug substance -
November 24, 2008
Third pivotal phase 3 study for Nicox naproxcinod shows positive efficacy, safety and blood pressure results -
November 12, 2008
Nicox naproxcinod shows highly significant reduction in daytime blood pressure versus naproxen -
November 04, 2008
Nicox announces favorable blood pressure data for naproxcinod in a large ABPM study -
October 22, 2008
Nicox reports results for the first three quarters of 2008 -
September 23, 2008
Nicox signs agreement with Capsugel for the commercial manufacture of naproxcinod oral capsules -
September 15, 2008
Nicox announces second naproxcinod pivotal phase 3 study (302) meets efficacy primary endpoints and supports non-detrimental blood pressure effect -
August 25, 2008
Nicox provides update on PF-03187207 and the ongoing research collaboration with Pfizer -
July 28, 2008
First half 2008 financial results: Nicox nears completion of phase 3 naproxcinod studies -
July 24, 2008
Nicox announces top-line results from naproxcinod 52-week 301 safety extension -
July 22, 2008
Nicox completes enrollment of two Ambulatory Blood Pressure Measurement (ABPM) studies for naproxcinod in hypertensive OA patients -
June 13, 2008
Nicox announces blood pressure analysis from 301 phase 3 study for naproxcinod at EULAR -
May 28, 2008
Nicox completes patient enrollment in third naproxcinod pivotal phase 3 study -
May 27, 2008
Nicox announces departure of Damian Marron for CEO position -
May 14, 2008
Nicox reports first quarter 2008 financial results -
May 13, 2008
Nicox announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc. -
May 06, 2008
Nicox announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program -
March 19, 2008
Nicox signs agreement for the commercial manufacture of naproxcinod drug substance -
March 03, 2008
Nicox initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis -
March 03, 2008
Financial results for full year 2007: Nicox significantly advances clinical programs -
January 08, 2008
Nicox signs extension of ophthalmology agreement with Pfizer -
January 03, 2008
Nicox announces Pfizer initiates phase 2 clinical development for PF-03187207 in Japan
See more 2007
-
December 14, 2007
Nicox completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update -
November 20, 2007
Nicox announces TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020 -
November 12, 2007
Nicox naproxcinod phase 3 results presented at American College of Rheumatology -
November 07, 2007
NicOx naproxcinod ABPM data presented at American Heart Association -
October 29, 2007
Nicox reports results for the first nine months of 2007 -
October 02, 2007
Nicox and Ferrer present promising clinical and preclinical results in dermatology -
September 11, 2007
Nicox reports TOPIGEN to advance TPI-1020 into phase 2 for COPD following promising clinical results -
July 30, 2007
First half 2007 financial results: Nicox strengthens balance sheet and advances naproxcinod -
July 16, 2007
Nicox receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic -
July 02, 2007
Nicox appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization -
June 29, 2007
Nicox initiates third pivotal naproxcinod phase 3 study -
June 18, 2007
Nicox provides an update on NCX 4016 -
May 11, 2007
Nicox provides an update on the phase 2a study for NCX 1000 conducted with Axcan -
May 11, 2007
Nicox reports first quarter 2007 financial results -
April 03, 2007
Nicox initiates second phase 3 study to confirm naproxcinod's efficacy and improved blood pressure profile -
March 29, 2007
Nicox announces that Pfizer has disclosed further details of glaucoma trial for PF-03187207 -
March 28, 2007
Clinical development initiated on lead compound in Nicox glaucoma collaboration with Pfizer -
March 01, 2007
Nicox 2006 financial results reflect a successful year of strong achievements and value creation -
February 14, 2007
Nicox announces the success of its €130 million rights issue -
February 12, 2007
Nicox presents promising pre-clinical results on an NO-donating latanoprost derivative from its glaucoma collaboration with Pfizer -
January 29, 2007
Nicox announces the terms of its rights issue to advance naproxcinod and broader pipeline -
January 22, 2007
Nicox launches a €130 million rights issue to advance naproxcinod and broader pipeline -
January 18, 2007
Nicox receives €5 million milestone payment from Merck & Co. for antihypertensive collaboration
See more 2006
-
December 08, 2006
Nicox ABPM trial shows favorable blood pressure profile for naproxcinod -
November 14, 2006
Nicox presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc. -
November 10, 2006
Nicox receives FDA feedback that no cardiovascular outcomes study required for naproxcinod NDA -
October 27, 2006
Nicox naproxcinod phase 3 OA trial meets primary endpoints and shows encouraging blood pressure profile -
October 17, 2006
Nicox confirms the EMEA agrees with its proposed naproxcinod safety database -
September 06, 2006
Nicox selects NCX 6560 for development - a new statin with broadened cardiovascular benefit -
September 06, 2006
Nicox gives full details of naproxcinod phase 3 plan in osteoarthritis and an update on other R&D programs -
August 03, 2006
Nicox completes enrolment ahead of schedule in ABPM trial for naproxcinod in hypertensive subjects -
July 26, 2006
Nicox to move NCX 4016 forward in phase 2 for diabetes -
July 26, 2006
Strong operational and financial achievement mark a transforming six months for Nicox -
June 22, 2006
Nicox announces patient enrolment ongoing in NCX 1000 phase 2 study -
June 19, 2006
Nicox receives WHO acceptance of naproxcinod as generic name for HCT 3012, first in a new class of treatments for osteoarthritis -
June 02, 2006
Nicox announces - 15 million equity investment by Pfizer -
May 24, 2006
Nicox completes enrolment of phase 3 trial for HCT 3012 in osteoarthritis ahead of schedule -
May 23, 2006
Nicox partner Topigen initiates phase 2 program for TPI-1020 in respiratory disorders -
May 16, 2006
Nicox and Ferrer select candidate for development in dermatology collaboration -
May 04, 2006
Nicox initiates new trial to establish HCT 3012 as osteoarthritis treatment with beneficial blood pressure profile -
April 28, 2006
Nicox announces fund raising of €45.5 million by private placement -
March 21, 2006
Nicox S.A. and Merck & Co., Inc. sign major exclusive worldwide agreement in antihypertensive field -
March 02, 2006
Nicox signs major new agreement with Pfizer for NO-donating compounds in ophthalmology -
March 02, 2006
Nicox compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration -
March 01, 2006
Nicox 2005 financial results: strong revenue growth and solid progress with clinical programs and partnerships
See more 2005
-
December 20, 2005
Nicox announces initiation of phase 3 trial for HCT 3012 in osteoarthritis -
November 22, 2005
Nicox announces Pfizer's exercise of option to developp lead compound from ophthalmology collaboration -
November 17, 2005
Nicox appoints PRA International - phase 3 program for HCT 3012 to be initiated -
November 16, 2005
Nicox announces presentation of NCX 4016 phase 2a results in type 2 diabetes at American Heart Association -
November 14, 2005
Nicox announces results of a phase 2 trial for NCX 4016 in PAOD -
November 02, 2005
Merck & Co., Inc. and Nicox extend Research Collaboration -
October 27, 2005
Nicox and Topigen sign agreement for NCX 1020 in COPD and other respiratory diseases -
September 15, 2005
Nicox and Ferrer expand collaboration in dermatology -
July 28, 2005
Nicox reports first-half 2005 financial results and provides a corporate update -
July 21, 2005
Nicox announces important progress in Ophthalmology collaboration with Pfizer -
July 11, 2005
Clinical trial shows promise with Nicox nitric oxide-donating compound in bone disease -
March 30, 2005
Nicox receives second payment under Pfizer Research, Option, Development and Licensing agreement -
March 15, 2005
Nicox's NCX 1020 achieves promising results in phase IIa for asthma -
March 01, 2005
Nicox reports 2004 financial results -
March 01, 2005
Nicox announces NCX 4016 more effective than aspirin at preventing platelet activation in diabetes in phase IIa study -
February 22, 2005
Nicox NCX 1510 partnered with Biolipox demonstrates rapid relief in new clinical trial -
February 14, 2005
Nicox selected to join European Community Network of Excellence, EICOSANOX -
January 20, 2005
Nicox announces full patient enrollment in phase II trial of NCX 4016 in PAOD
See more 2004
-
December 21, 2004
Dr. Göran Ando joins Nicox Board of Directors -
December 15, 2004
Nicox to proceed with phase III development of lead CINOD HCT 3012 following positive end phase II meeting with FDA -
September 30, 2004
Nicox announces successful fund raising of 26 million euros by private placement -
September 08, 2004
Nicox initiates clinical study to evaluate HCT 3012 effects on blood pressure vs.rofecoxib -
August 26, 2004
Nicox, Pfizer sign Research, Option, Development and Licensing Agreement -
July 28, 2004
Nicox reports first-half 2004 financial results -
June 10, 2004
Nicox's HCT 3012 shows equivalent efficacy to rofecoxib without any increase of Systolic Blood Pressure in osteoarthritis patient -
June 01, 2004
Nicox informs: NCX 1510 successfully achieves primary endpoint in clinical Phase II trial in rhinitis -
April 29, 2004
Nicox forms strategic alliance with Ferrer in dermatology - Promising Phase II clinical efficacy results announced for lead compound NCX 1022. -
April 14, 2004
Nicox's Alzheimer drug candidate shown to reduce key component of Alzheimer's Disease -
February 26, 2004
Nicox reports year-end 2003 financial results -
January 27, 2004
Nicox announces positive evaluation of overall phase II clinical results on AZD3582 by a U.S. Consultant Advisory Board -
January 21, 2004
First Nicox compound in Biolipox collaboration enters phase II -
January 08, 2004
NCX 4016 successfully achieves primary efficacy endpoint in Phase II clinical study of symptomatic peripheral arterial obstructive disease (PAOD)
See more 2003
-
September 23, 2003
Nicox to reacquire to CINOD class of drugs from AstraZeneca -
September 09, 2003
Nicox: Clinical study with NCX 4016 showing nitric oxide protects against aspirin-induced gastric damage to be presented at AHA meeting -
August 19, 2003
Merck & Co., Inc. and Nicox form research collaboration on Nitric Oxide-donating drugs -
July 24, 2003
Nicox reports first-half 2003 financial results -
June 18, 2003
Nicox: Successful Phase II efficacy results with NCX 701 in acute pain -
May 21, 2003
Clinical results show Nicox's NCX 4016 maintains excellent gastric safety in co-administration with celecoxib -
May 13, 2003
Nicox announces successful Phase I clinical results with HCT 1026 in development for Alzheimer's disease -
April 01, 2003
Nicox NCX 1020 begins clinical development in respiratory disease -
March 26, 2003
Further update on AZD3582 following meeting of independent Panel -
March 13, 2003
Nicox announces National Cancer Institute grant for a human clinical trial of NCX 4016 in prevention of colon cancer -
March 11, 2003
Nicox announces preliminary review of data from Phase II study of AZD3582 -
March 03, 2003
Nicox reports year-end 2002 financial results -
February 24, 2003
Nicox has requested an investigation from the "Commission des Opérations de Bourse". -
February 20, 2003
Nicox requests full data file on AZD3582 -
February 18, 2003
Nicox: Research Update on AZD3582 -
February 05, 2003
Nicox and Axcan granted US IND for Phase I clinical studies on NCX 1000 -
January 29, 2003
Nicox and Biolipox expand research collaboration on novel nitric oxide-donating compounds for the treatment of respiratory diseases.
See more 2002
-
December 13, 2002
Jean-Luc Bélingard, President and CEO of Beaufour-Ipsen, joins Nicox Board of Directors -
November 07, 2002
Nicox informs: Positive Phase II clinical data in acute pain presented on AZD3582 -
November 07, 2002
AZD4717 selected as second lead compound from CINOD class by AstraZeneca et Nicox -
October 24, 2002
Nicox granted US IND for Phase II trials with NCX 4016 in cardiovascular diseases -
September 30, 2002
Nicox signs Exclusive Agreement with AstraZeneca for the development of AZD3582 and other CINOD in Japan -
September 17, 2002
Nicox granted US IND for Phase II clinical testing of NCX 701 in acute pain -
July 25, 2002
Nicox reports first half 2002 financial results -
July 08, 2002
Nicox announces first clinical results for inhaled NCX 950 in respiratory diseases -
June 14, 2002
Nicox announces a three-for-one stock split -
May 23, 2002
Nicox and Axcan sign co-development and license agreement for NCX 1000 in the treatment of chronic liver diseases -
May 22, 2002
Nicox's Nitric Oxide-donating Aspirin is Safe for the Gastrointestinal Tract in Humans -
May 21, 2002
Nicox informs: first gastrointestinal data presented on AZD3582, the first of a potential new class of pain medications -
April 16, 2002
Positive Phase I/IIa clinical results for nitric oxide-donating aspirin showing novel inhibition of vascular inflammation and platelet activation -
April 02, 2002
Nicox announces positive phase IIa clinical results for HCT 1026 in overactive bladder -
February 22, 2002
Nicox reports year end 2001 financial results -
February 14, 2002
Nicox announces positive Phase I results and new pre-clinical data on NCX 1015 -
January 07, 2002
Nicox granted IND status for clinical testing of HCT 1026 in the US
See more 2001
-
November 14, 2001
Nicox announces start of pilot Phase II trial for NO-aspirin in treatment of insulin resistance and associated vascular impairments after promising preclinical data -
September 27, 2001
Promising preclinical results for new NO-releasing compounds -
September 19, 2001
Nicox Research Center opens in northern Italy -
July 26, 2001
Nicox reports first half 2001 financial results -
July 09, 2001
Nicox's NO-releasing chemopreventive agents receive second research grant from U.S. National Cancer Institute -
July 02, 2001
Vaughn M. Kailian, President and CEO of COR Therapeutics Inc., joins Nicox Board of Directors -
June 27, 2001
Nicox: positive Phase I clinical results for the first administration into man of NCX 701 -
June 25, 2001
Nicox and Biolipox enter into research collaboration -
May 14, 2001
Nicox's Nitric Oxide-Releasing Steroid, NCX 1022, Shows Promising Clinical Results in Skin Blanching -
April 18, 2001
Nicox's HCT 1026 shows positive clinical dermatology results in prolonged contact urticaria -
March 27, 2001
Publication in Proceedings National Academy of Sciences of USA (PNAS) shows new cell proliferation inhibitory properties by Nitric Oxide donors -
March 08, 2001
Frank Baldino, Chairman and CEO of Cephalon Inc., joins Nicox Board of Directors -
March 08, 2001
Financial results 2000 - Nicox reports increased revenues and decreased net loss -
February 27, 2001
Publication in the Proceedings National Academy of Sciences of USA (PNAS) reports that NCX-4016 reduces restenosis in vivo -
February 08, 2001
NO-aspirins inhibit human colon and pancreatic cancer cell growth in vitro -
January 24, 2001
Nicox's HCT-3012 advances into Phase II Human Clinical Trials. Company receives US$ 3 million Milestone Payment from AstraZeneca
See more 2000
-
December 18, 2000
Three Nicox drug candidates advance into phase I clinical trials -
December 11, 2000
Nicox presents positive preclinical data on anti-inflammatory and neuroprotective effects of NCX-2216 -
November 28, 2000
HCT 1026 shows positive clinical results in the treatment of skin inflammation -
November 21, 2000
NO-Aspirin (NCX 4016) effective in preventing vein graft failure in animal models -
October 18, 2000
NCX-4016 reduces myocardial infarct size in anaesthetised pigs subjected to ischaemia / reperfusion -
September 21, 2000
Nicox announces National Cancer Institute research grant to study cancer prevention with its NO-releasing chemopreventive agents -
July 31, 2000
Nicox reports first half 2000 financial results -
July 19, 2000
Preclinical results announced for Alzheimer s drug, NCX 2216. Data presented at the 7th International Conference on Alzheimer's -
July 03, 2000
Nicox announces positive preliminary phase I/II results in contact urticaria. Commences second dermatology study -
June 09, 2000
Nicox announces positive pre-clinical results for NO-paracetamol (NCX 701) -
May 25, 2000
Nicox announces positive pre-clinical results in liver disease with NCX 1000 presented at the American Gastroenterological Association Congress in San Diego -
May 19, 2000
Nicox receives Milestone Payment from AstraZeneca for initiation of Phase 1 Trial of HCT-3012 -
May 12, 2000
HCT 1026: Advancement of clinical trials in overactive bladder Encouraging phase II preliminary results in neurogenic bladder -
April 20, 2000
Nicox Granted CTX for HCT-1026 by UK Medicines Control Agency in urinary incontinence -
March 20, 2000
Nicox reports year end 1999 financial results -
March 15, 2000
Nicox initiates human clinical trials in dermatology with HCT-1026 -
February 21, 2000
New oral formulation of NCX 4016 (NO-aspirin) Initiates Phase I Clinical trials in France -
January 27, 2000
Nicox granted IND by US Food and Drug Administration for NCX 4016 (NO-aspirin)
See more 1999
-
December 20, 1999
Nicox initiates Phase II trial with HCT-1026 in Paget's disease -
November 03, 1999
Nicox S.A. Lists On French Nouveau Marché -
October 27, 1999
Nicox amends structure of its Nouveau Marché Initial Public Offering -
October 11, 1999
Nicox, leader in the development of nitric oxide-releasing drugs, announces its intention to list its shares on the Paris Stock Exchange "Nouveau Marché" -
July 26, 1999
Nicox initiates Phase II trial with HCT-1026 for urinary incontinence
See more 1998
-
December 09, 1998
Nicox awarded 1998 AFIC Prize for Innovation -
November 30, 1998
Nicox Makes Two New Board Members Appointments -
October 13, 1998
Nobel Prize for Research on Nitric Oxide, awarded to a Member of the Scientific Advisory Board of Nicox S.A. -
October 02, 1998
Nicox Signs Exclusive Licence Agreement for NO-NSAIDs with Astra -
July 15, 1998
Nicox appoints Chief Financial Officer and moves headquarters to France -
April 27, 1998
Nicox appoints Professor Salvador Moncada to Board of Directors -
March 05, 1998
Bayer and Nicox enter into research collaboration
See more 1997
See more 1996